A clinical hold is a regulatory action taken by the U.S. Food and Drug Administration (FDA) to temporarily suspend or delay a clinical trial. This action is typically implemented when the FDA identifies potential safety concerns or other issues that require further investigation or resolution before the trial can proceed.
During a clinical hold, no new participants can be enrolled in the study, and existing participants must not receive the investigational product. The sponsor of the clinical trial must address the FDA’s concerns and provide additional information or make necessary changes before the hold can be lifted and the trial allowed to continue.
The term ‘clinical hold’ is crucial in clinical research as it serves as a critical safety mechanism to protect study participants and ensure the integrity of clinical trials. It allows regulatory bodies to intervene when potential risks or concerns arise, ensuring that patient safety remains the top priority throughout the research process.
Understanding clinical holds is essential for sponsors, investigators, and other stakeholders in clinical research to navigate regulatory requirements effectively. It emphasizes the importance of rigorous study design, thorough safety monitoring, and prompt addressing of any issues raised by regulatory authorities to maintain the progress and validity of clinical trials.
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
Copyright @ 2026 Axcellant